Microbix, Angiogen to commercialize urokinase product for treating cancer

By Elaine Rigoli

Tampa, Fla., April 4 - Microbix Biosystems, Inc. and Angiogen LLC have signed a worldwide exclusive agreement to commercialize a proprietary technology that has shown promise for treating prostate, colon and other human cancers.

Angiogen is providing exclusive rights to its patented technology, which uses urokinase in a cocktail containing an additional Food and Drug Administration-approved small chemical drug, according to a news release.

Once inside the body, this angiostatic cocktail generates the anticancer agent angiostatin 4.5 (AS4.5), which destroys specific blood vessels, thereby removing the blood supply that nourishes the tumor, the release said.

The cancer cells are then starved of the energy needed to survive and grow.

Microbix will be the exclusive supplier of this product for all oncology indications. Microbix and Angiogen will jointly pursue third-party pharmaceutical partners for oncology applications, and they expect that the first commercial application of the drug will be for metastatic prostate cancer.

Angiogen will receive a royalty from sales of the angiostatic cocktail, and Microbix will generate revenue by supplying urokinase used in the combination, the release said.

Microbix, based in Toronto, Ont., specializes in developing proprietary biological technologies.

Based in Chicago, Angiogen is a biopharmaceutical company developing novel treatments for solid, vascular cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.